z-logo
open-access-imgOpen Access
EPH-EPHRIN in human gastrointestinal cancers
Author(s) -
Haruhiko Sugimura,
Jiandong Wang,
Hiroki Mori,
Masaru Tsuboi,
Kiyoko Nagura,
Hisaki Igarashi,
Tao Hong,
Ritsuko Nakamura,
Hiroko Natsume,
Tomoaki Kahyo,
Kazuya Shinmura,
Hiroyuki Konno,
Yasushi Hamaya,
Shigeru Kanaoka,
Hideki Kataoka,
Xiaojun Zhou
Publication year - 2010
Publication title -
world journal of gastrointestinal oncology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 26
ISSN - 1948-5204
DOI - 10.4251/wjgo.v2.i12.421
Subject(s) - erythropoietin producing hepatocellular (eph) receptor , ephrin , eph receptor a2 , medicine , cancer research , cancer , angiogenesis , bioinformatics , biology , receptor , receptor tyrosine kinase
Ever since its discovery two decades ago, the erythropoietin-producing hepatoma (EPH)-EPHRIN system has been shown to play multifaceted roles in human gastroenterological cancer as well as neurodevelopment. Over-expression, amplification and point mutations have been found in many human cancers and many investigators have shown correlations between these up-regulations and tumor angiogenesis. Thus, the genes in this family are considered to be potential targets of cancer therapy. On the other hand, the down-regulation of some members as a result of epigenetic changes has also been reported in some cancers. Furthermore, the correlation between altered expressions and clinical prognosis seems to be inconclusive. A huge amount of protein-protein interaction studies on the EPH-EPHRIN system have provided a basic scheme for signal transductions, especially bi-directional signaling involving EPH-ERPHRIN molecules at the cell membrane. This information also provides a manipulative strategy for harnessing the actions of these molecules. In this review, we summarize the known alterations of EPH-EPHRIN genes in human tumors of the esophagus, stomach, colorectum, liver and pancreas and present the perspective that the EPH-EPHRIN system could be a potential target of cancer therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here